Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Lymphoma, T-Cell, Peripheral 3Myelodysplastic Syndromes 2Lymphoma, T-Cell 2Leukemia, Myeloid, Acute 2Uveal Melanoma 1Neuroendocrine Tumors 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Eye Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Neuroendocrine 1Blast Crisis 1

Interventions

Nivolumab 11pembrolizumab 10Ipilimumab 9Cyclophosphamide 6tebentafusp 5Interleukin-2 4Blood Specimen Collection 4fludarabine phosphate 3fludarabine 3Specimen Handling 3Radiosurgery 3Melphalan 3Magnetic Resonance Spectroscopy 3relatlimab 2lenvatinib 2cemiplimab 2binimetinib 2aflibercept 2Surveys and Questionnaires 2Dacarbazine 2Crizotinib 2Carmustine 2Biopsy 2ulixertinib 1trametinib 1sargramostim 1ruxolitinib 1omipalisib 1olaparib 1lifileucel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uveal Melanoma × belinostat × 1 year × Clear all
NCT05170334 2026-04-06

Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
7 enrolled
Dermatologic

Uveal Melanoma, Eye Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡